Contribution of the Interferon score in the management of an anti-NXP2 dermatomyositis patient with calcinosis successfully treated with tofacitinib.

• The IFN score can drive the use of tofacitinib in dermatomyositis (DM). • Tofacitinib should be considered for DM patients with refractory calcinosis. • Prolonged treatment with tofacitinib is required to allow regression of calcinosis. [ABSTRACT FROM AUTHOR]